Patient characteristics and genotype
| . | Cases, n (%) . | Controls, n (%) . |
|---|---|---|
| Total | 43 (100) | 67 (100) |
| Male | 27 (62.8) | 43 (64.2) |
| Female | 16 (37.2) | 24 (35.8) |
| Older than 10 y | 37 (86.0) | 58 (85.6) |
| NCI high-risk | 39 (90.7) | 62 (92.5) |
| Augmented BFM therapy* | 11 (25.6) | 18 (26.9) |
| Genotype | ||
| GG | 34 (79.1) | 51 (76.1) |
| GA | 8 (18.6) | 16 (23.9) |
| AA | 1 (2.3) | 0 (0) |
| . | Cases, n (%) . | Controls, n (%) . |
|---|---|---|
| Total | 43 (100) | 67 (100) |
| Male | 27 (62.8) | 43 (64.2) |
| Female | 16 (37.2) | 24 (35.8) |
| Older than 10 y | 37 (86.0) | 58 (85.6) |
| NCI high-risk | 39 (90.7) | 62 (92.5) |
| Augmented BFM therapy* | 11 (25.6) | 18 (26.9) |
| Genotype | ||
| GG | 34 (79.1) | 51 (76.1) |
| GA | 8 (18.6) | 16 (23.9) |
| AA | 1 (2.3) | 0 (0) |
NCI indicates National Cancer Institute; and BFM, Berlin-Frankfurt-Münster.
Augmented BFM therapy is described in Seibel et al4 and corresponds to UKALL 2003 regimen C.